公司概覽
業務類別 --
業務概覽 Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
公司地址 46, Avenue de la Great Army, Paris, FRA, 75017
電話號碼 +33 153774000
傳真號碼 +33 153774303
公司網頁 https://www.sanofi.com
員工數量 74846
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Manuela Buxo Executive Vice President, Specialty Care -- 17/02/2026
Mr. Roy Papatheodorou Executive Vice President and General Counsel -- 17/02/2026
Mr. Emmanuel Frenehard Executive Vice President and Chief Digital Officer -- 17/02/2026
Mr. Houman Ashrafian Executive Vice President and Head of Research and Development -- 17/02/2026
Mr. Brendan O'Callaghan Executive Vice President, Global Manufacturing and Supply -- 17/02/2026
Mr. Francois-Xavier Roger Executive Vice President and Chief Financial Officer -- 17/02/2026
Ms. Natalie Bickford Executive Vice President and Chief People Officer -- 17/02/2026
Ms. Audrey Duval Executive Vice President, Corporate Affairs -- 17/02/2026
Mr. Olivier Charmeil Executive Vice President, General Medicines and Interim Chief Executive Officer -- 17/02/2026
Ms. Madeleine Roach Executive Vice President, Business Operations -- 17/02/2026
Mr. Thomas Triomphe Executive Vice President, Vaccines -- 17/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Emile Voest Independent Director 17/02/2026
Ms. Barbara Lavernos Director 17/02/2026
Mr. Wolfgang Laux Director 17/02/2026
Ms. Clotilde Delbos Independent Director 17/02/2026
Ms. Carole Ferrand Independent Director 17/02/2026
Ms. Rachel Duan Independent Director 17/02/2026
Dr. Antoine Yver, M.D.,M.Sc. Independent Director 17/02/2026
Mr. John Sundy Independent Director 17/02/2026
Mr. Christophe Babule Director 17/02/2026
Ms. Anne-Francoise Nesmes Independent Director 17/02/2026
Mr. Patrick Kron Independent Director 17/02/2026
Mr. Humberto De Sousa Director 17/02/2026
Mr. Paul Hudson Director 17/02/2026
Mr. Frederic Oudea Chairman of the Board 17/02/2026
Ms. Lise Kingo Independent Director 17/02/2026
Mr. Jean-Paul Kress, M.D. Independent Director 17/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:14)
代號 名稱 佔比% 持有日期
FENIFidelity Enhanced International ETF0.05%27/02/2026
IXJiShares Global Healthcare ETF0.05%28/02/2026
IEURiShares Core MSCI Europe ETF0.04%28/02/2026
IVLUiShares Edge MSCI Intl Value Factor ETF0.04%28/02/2026
DFAIDimensional International Cr Eq Mkt ETF0.04%27/02/2026
EFAViShares MSCI EAFE Min Vol Factor ETF0.04%25/02/2026
DBEFXtrackers MSCI EAFE Hedged Equity ETF0.04%24/02/2026
BBINJPMorgan BetaBuilders Intl Eq ETF0.03%27/02/2026
ACWIiShares MSCI ACWI ETF0.03%28/02/2026
ACWXiShares MSCI ACWI ex US ETF0.02%28/02/2026
IGROiShares International Dividend Gr ETF0.02%28/02/2026
DIVIFranklin Intl Core Div Tlt Idx ETF0.02%28/02/2026
IOOiShares Global 100 ETF0.02%28/02/2026
XTiShares Future Exponential Techs ETF0.02%28/02/2026
CGICCapital Group International Cor Eq ETF0.02%31/01/2026
VSGXVanguard ESG International Stock ETF0.02%31/01/2026
CGXUCapital Group International Focus Eq ETF0.02%31/01/2026
DFICDimensional International Core Eq 2 ETF0.02%27/02/2026
BDJBlackRock Enhanced Equity Div0.01%31/12/2025
PXFInvesco RAFI Developed Markets ex-US ETF0.01%24/02/2026
  1   2    3    4    5    6    7    8    9  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.